Do analysts rate ZYBT or NXTC?

NextCure has a consensus target price of $19.00, suggesting a potential upside of 228.72%. Given NextCure's stronger consensus rating and higher possible upside, analysts clearly believe NextCure is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger valuation & earnings, ZYBT or NXTC?

Zhengye Biotechnology has higher revenue and earnings than NextCure. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 3.65 -$9.98M N/A N/A NextCure N/A N/A -$55.84M -$17.19 N/A

Is ZYBT or NXTC more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A NextCure N/A -186.96% -124.62%

Which has preferable earnings and valuation, NXTC or IBIO?

iBio has higher revenue and earnings than NextCure. iBio is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NextCure N/A N/A -$55.84M -$17.19 N/A iBio $300K 241.77 -$18.38M -$0.58 N/A

Is NXTC or IBIO more profitable?

iBio's return on equity of -53.86% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -186.96% -124.62% iBio N/A -53.86% -46.48%

Does the media favor NXTC or IBIO?

In the previous week, NextCure had 6 more articles in the media than iBio. MarketBeat recorded 8 mentions for NextCure and 2 mentions for iBio. NextCure's average media sentiment score of 1.43 beat iBio's score of 1.00 indicating that NextCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, NXTC or ENLV?

NextCure is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NextCure N/A N/A -$55.84M -$17.19 N/A Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A

Is NXTC or ENLV more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -186.96% -124.62% Enlivex Therapeutics N/A 248.08% 206.39%

Does the media refer more to NXTC or ENLV?

In the previous week, NextCure had 7 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 8 mentions for NextCure and 1 mentions for Enlivex Therapeutics. NextCure's average media sentiment score of 1.43 beat Enlivex Therapeutics' score of 0.00 indicating that NextCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, CLNN or NXTC?

Clene has higher revenue and earnings than NextCure. Clene is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clene $200K 337.39 -$26.17M -$3.20 N/A NextCure N/A N/A -$55.84M -$17.19 N/A

Is CLNN or NXTC more profitable?

NextCure has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Clene -25,009.70% N/A -137.98% NextCure N/A -186.96% -124.62%

Does the media prefer CLNN or NXTC?

In the previous week, NextCure had 7 more articles in the media than Clene. MarketBeat recorded 8 mentions for NextCure and 1 mentions for Clene. NextCure's average media sentiment score of 1.43 beat Clene's score of 0.00 indicating that NextCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NextCure 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NXTC or ATRA?

In the previous week, NextCure had 7 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 8 mentions for NextCure and 1 mentions for Atara Biotherapeutics. NextCure's average media sentiment score of 1.43 beat Atara Biotherapeutics' score of 0.84 indicating that NextCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atara Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NextCure (NXTC) Competitors

$5.78 +1.38 (+31.36%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$5.70 -0.08 (-1.40%)

As of 04:05 AM Eastern

Compare

NXTC vs. ZYBT, IBIO, ENLV, CLNN, and ATRA

Should you buy NextCure stock or one of its competitors? MarketBeat compares NextCure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NextCure include Zhengye Biotechnology (ZYBT), iBio (IBIO), Enlivex Therapeutics (ENLV), Clene (CLNN), and Atara Biotherapeutics (ATRA).

How does NextCure compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Zhengye Biotechnology's return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
NextCure	N/A	-186.96%	-124.62%

42.7% of NextCure shares are owned by institutional investors. 11.9% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Zhengye Biotechnology has higher revenue and earnings than NextCure.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	3.65	-$9.98M	N/A	N/A
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

Zhengye Biotechnology has a beta of -2.72, suggesting that its share price is 372% less volatile than the broader market. Comparatively, NextCure has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

NextCure has a consensus target price of $19.00, suggesting a potential upside of 228.72%. Given NextCure's stronger consensus rating and higher possible upside, analysts clearly believe NextCure is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, NextCure had 8 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 8 mentions for NextCure and 0 mentions for Zhengye Biotechnology. NextCure's average media sentiment score of 1.43 beat Zhengye Biotechnology's score of 0.00 indicating that NextCure is being referred to more favorably in the news media.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
NextCure	Positive

Summary

NextCure beats Zhengye Biotechnology on 8 of the 12 factors compared between the two stocks.

How does NextCure compare to iBio?

NextCure (NASDAQ:NXTC) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

iBio has higher revenue and earnings than NextCure. iBio is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A
iBio	$300K	241.77	-$18.38M	-$0.58	N/A

iBio's return on equity of -53.86% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-186.96%	-124.62%
iBio	N/A	-53.86%	-46.48%

42.7% of NextCure shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 11.9% of NextCure shares are owned by insiders. Comparatively, 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NextCure presently has a consensus target price of $19.00, suggesting a potential upside of 228.72%. iBio has a consensus target price of $5.00, suggesting a potential upside of 242.47%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

NextCure has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, iBio has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

In the previous week, NextCure had 6 more articles in the media than iBio. MarketBeat recorded 8 mentions for NextCure and 2 mentions for iBio. NextCure's average media sentiment score of 1.43 beat iBio's score of 1.00 indicating that NextCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NextCure	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iBio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

iBio beats NextCure on 10 of the 15 factors compared between the two stocks.

How does NextCure compare to Enlivex Therapeutics?

NextCure (NASDAQ:NXTC) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

NextCure presently has a consensus price target of $19.00, suggesting a potential upside of 228.72%. Enlivex Therapeutics has a consensus price target of $247.50, suggesting a potential upside of 11,629.86%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Enlivex Therapeutics' return on equity of 248.08% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-186.96%	-124.62%
Enlivex Therapeutics	N/A	248.08%	206.39%

NextCure is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

In the previous week, NextCure had 7 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 8 mentions for NextCure and 1 mentions for Enlivex Therapeutics. NextCure's average media sentiment score of 1.43 beat Enlivex Therapeutics' score of 0.00 indicating that NextCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NextCure	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NextCure has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

42.7% of NextCure shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 11.9% of NextCure shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Enlivex Therapeutics beats NextCure on 10 of the 14 factors compared between the two stocks.

How does NextCure compare to Clene?

Clene (NASDAQ:CLNN) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

23.3% of Clene shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 28.3% of Clene shares are owned by insiders. Comparatively, 11.9% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, NextCure had 7 more articles in the media than Clene. MarketBeat recorded 8 mentions for NextCure and 1 mentions for Clene. NextCure's average media sentiment score of 1.43 beat Clene's score of 0.00 indicating that NextCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NextCure	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Clene presently has a consensus price target of $33.25, suggesting a potential upside of 529.73%. NextCure has a consensus price target of $19.00, suggesting a potential upside of 228.72%. Given Clene's stronger consensus rating and higher possible upside, equities research analysts plainly believe Clene is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Clene has higher revenue and earnings than NextCure. Clene is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	337.39	-$26.17M	-$3.20	N/A
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

Clene has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, NextCure has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

NextCure has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-25,009.70%	N/A	-137.98%
NextCure	N/A	-186.96%	-124.62%

Summary

Clene beats NextCure on 8 of the 15 factors compared between the two stocks.

How does NextCure compare to Atara Biotherapeutics?

NextCure (NASDAQ:NXTC) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

NextCure has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Atara Biotherapeutics' return on equity of -79.12% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-186.96%	-124.62%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

42.7% of NextCure shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 11.9% of NextCure shares are owned by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Atara Biotherapeutics has higher revenue and earnings than NextCure. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A
Atara Biotherapeutics	$120.77M	0.65	$32.69M	-$0.67	N/A

NextCure has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

NextCure presently has a consensus target price of $19.00, suggesting a potential upside of 228.72%. Atara Biotherapeutics has a consensus target price of $9.50, suggesting a potential upside of 8.32%. Given NextCure's stronger consensus rating and higher possible upside, equities research analysts plainly believe NextCure is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, NextCure had 7 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 8 mentions for NextCure and 1 mentions for Atara Biotherapeutics. NextCure's average media sentiment score of 1.43 beat Atara Biotherapeutics' score of 0.84 indicating that NextCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NextCure	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atara Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NextCure beats Atara Biotherapeutics on 8 of the 15 factors compared between the two stocks.

Get NextCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NXTC vs. The Competition

Export

Metric	NextCure	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.89M	$3.52B	$6.83B	$12.76B
Dividend Yield	N/A	3.77%	2.59%	10.01%
P/E Ratio	-0.34	7.32	279.15	25.53
Price / Sales	N/A	1,296.62	595.58	92.32
Price / Cash	N/A	103.44	72.11	49.39
Price / Book	0.58	17.36	13.06	6.11
Net Income	-$55.84M	-$12.52M	$3.48B	$347.58M
7 Day Performance	15.14%	3.69%	3.40%	4.91%
1 Month Performance	207.45%	-5.34%	-2.79%	-2.06%
1 Year Performance	11.15%	49.49%	73.10%	21.03%

NextCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NXTC NextCure	4.144 of 5 stars	$5.78 +31.4%	$19.00 +228.7%	+14.7%	$15.89M	N/A	N/A	90	Positive News Upcoming Earnings Insider Trade Gap Up
ZYBT Zhengye Biotechnology	0.2068 of 5 stars	$1.33 -13.1%	N/A	-77.8%	$72.51M	$16.64M	N/A	278	Gap Down
IBIO iBio	2.6079 of 5 stars	$1.39 -4.1%	$5.00 +259.7%	N/A	$72.03M	$400K	N/A	100	News Coverage Positive News
ENLV Enlivex Therapeutics	2.8784 of 5 stars	$2.24 -47.4%	$247.50 +10,949.1%	-90.5%	$71.70M	N/A	N/A	70	Gap Up High Trading Volume
CLNN Clene	2.0758 of 5 stars	$4.99 -8.6%	$33.25 +566.3%	+41.2%	$69.77M	$200K	N/A	100	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NXTC) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NextCure (NXTC) Competitors

NXTC vs. ZYBT, IBIO, ENLV, CLNN, and ATRA

How does NextCure compare to Zhengye Biotechnology?

Summary

How does NextCure compare to iBio?

Summary

How does NextCure compare to Enlivex Therapeutics?

Summary

How does NextCure compare to Clene?

Summary

How does NextCure compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC vs. The Competition

NextCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NextCure (NXTC) Competitors

NXTC vs. ZYBT, IBIO, ENLV, CLNN, and ATRA

How does NextCure compare to Zhengye Biotechnology?

Is ZYBT or NXTC more profitable?

Do insiders and institutionals hold more shares of ZYBT or NXTC?

Which has stronger valuation & earnings, ZYBT or NXTC?

Which has more volatility & risk, ZYBT or NXTC?

Do analysts rate ZYBT or NXTC?

Does the media favor ZYBT or NXTC?

Summary

How does NextCure compare to iBio?

Which has preferable earnings and valuation, NXTC or IBIO?

Is NXTC or IBIO more profitable?

Do institutionals and insiders hold more shares of NXTC or IBIO?

Do analysts rate NXTC or IBIO?

Which has more volatility & risk, NXTC or IBIO?

Does the media favor NXTC or IBIO?

Summary

How does NextCure compare to Enlivex Therapeutics?

Do analysts rate NXTC or ENLV?

Is NXTC or ENLV more profitable?

Which has higher earnings and valuation, NXTC or ENLV?

Does the media refer more to NXTC or ENLV?

Which has more volatility & risk, NXTC or ENLV?

Do insiders and institutionals hold more shares of NXTC or ENLV?

Summary

How does NextCure compare to Clene?

Do institutionals and insiders hold more shares of CLNN or NXTC?

Does the media prefer CLNN or NXTC?

Do analysts recommend CLNN or NXTC?

Which has better earnings & valuation, CLNN or NXTC?

Which has more volatility and risk, CLNN or NXTC?

Is CLNN or NXTC more profitable?

Summary

How does NextCure compare to Atara Biotherapeutics?

Is NXTC or ATRA more profitable?

Do institutionals & insiders hold more shares of NXTC or ATRA?

Which has better valuation and earnings, NXTC or ATRA?

Which has more volatility and risk, NXTC or ATRA?

Do analysts prefer NXTC or ATRA?

Does the media refer more to NXTC or ATRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC vs. The Competition

NextCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools